Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant
临床前开发一种核靶向生物制剂,可安全地增加干细胞体内扩增,以加速化疗和骨髓移植后中性粒细胞减少症的恢复
基本信息
- 批准号:10685290
- 负责人:
- 金额:$ 23.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-17 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:ANXA5 geneAccelerationAdverse effectsAdverse eventAftercareApoptosisApoptoticBiologicalBiological AssayBloodBone MarrowBone Marrow DiseasesBone Marrow TransplantationCD34 geneCell NucleusCell TransplantationCellsChemotherapy and/or radiationChimeric ProteinsChimerismClinicClinicalClinical TrialsComplexConsumptionDataDiseaseDoseDyesEngraftmentExcisionExploratory/Developmental Grants Phase IIExposure toFemaleFluorescence MicroscopyFutureGelGeneticGoalsHalf-LifeHela CellsHematopoieticHematopoietic NeoplasmsHematopoietic Stem Cell TransplantationHematopoietic stem cellsHomeodomain ProteinsHospitalizationHourHumanImmune systemImmunodeficient MouseIn VitroInfectionInflammatoryInpatientsIntravenous infusion proceduresLeadLegal patentLibrariesLifeMalignant Bone Marrow NeoplasmMeasuresMethodologyMethodsModelingMonitorMucositisMusMyelogenousMyeloproliferative diseaseNecrosisNeutropeniaNuclearPatient-Focused OutcomesPatientsPenetrationPeptidesPharmaceutical PreparationsPhasePredispositionProliferatingProteinsRecoveryResistanceRiskSafetyScanningSiteSourceStainsSystemTherapeuticTimeToxic effectToxicologyTransplant RecipientsTransplantationTransplantation Conditioningcandidate identificationcandidate selectionchemotherapyclinical investigationcomparison controlconditioningcostcytotoxicityefficacy evaluationefficacy studyexperiencehematopoietic stem cell expansionhigh riskimprovedin vivoinfection riskinnovationlead candidatemalemanmanufacturemutantnoveloverexpressionperipheral bloodpost-transplantpre-clinicalpreclinical developmentreconstitutionsafety studyscreeningstem cell expansionstem cell functiontranscription factoruptake
项目摘要
Hematopoietic stem cell (HSC) transplants (HSCTs) are considered a potentially curative option for patients with
certain cancers of the blood and bone marrow and over 20,000 HSCTs are performed in the US each year.
However, HSCTs are associated with high risk due to the required removal of diseased bone marrow before
transplantation. Until the transplanted cells engraft and proliferate enough to reconstitute the patient’s immune
system, the patient is considered neutropenic during which they are highly susceptible to infection. In addition to
the potentially life-threatening physical risk to the patient, neutropenia necessitates long hospitalization time that
can in part drives the expensive cost of HSCTs ranging up to $400,000 in the US. A current strategy in clinical
trials is to transplant larger pools of donor HSCs to shorten the neutropenic phase. However, these approaches
all rely on ex vivo culturing of donor cells that depend on imperfect man-made culture systems that may disrupt
the proper function of the stem cells and can be prohibitively expensive. Ship of Theseus’ innovative solution is
a drug that will be used for a brief, one-time exposure to donor cells prior to transplantation that improves
expansion in vivo. Our drug is a patented mutant of nuclear transcription factor, Homeobox protein B4
(HOXB4(m)), which promotes HSC expansion without differentiation. HOXB4(m) has improved degradation
resistance, which enables us to overcome several shortcomings of HOXB4 (e.g., short protein half-life and
myeloproliferative disorders associated with genetic overexpression). By elongating its intracellular half-life,
HOXB4(m) is practical for clinical use while potentially avoiding adverse effects induced by constitutive
overexpression. Early preclinical data indicating treating cells with HOXB4(m) can expand all major lineages of
HSCs while maintaining multipotency. However, current delivery of HOXB4(m) is limited by its ability to penetrate
cells and localize in the nucleus, the site of its bioactivity.
The goal of this R61/R33 proposal is to improve efficiency and safety of HOXB4(m) by improving its nuclear
delivery. This will be accomplished through the execution of 3 aims. In Aim 1 (R61), we will perform a library
screen to identify optimal combinations of cell penetrating peptide and nuclear targeting motifs for HOXB4(m)
nuclear localization. In Aim 2 (R33), we will assess in vitro efficacy of the top candidates to select a lead
candidate. In Aim 3 (R33), we will demonstrate long-term hematopoietic reconstitution without adverse effects
or GVHD of our lead candidate in vivo in a mouse HSCT study. Successful completion of this R61/R33 program
will demonstrate feasibility of an improved HOXB4(m) candidate that maintains efficacy at lower concentrations
and briefer exposure periods. This project will provide the necessary data to support future extensive in vivo
efficacy and safety studies necessary for an IND submission. With HOXB4(m), we can circumvent the original
hurdles of HOXB4 and improve expansion in vivo to benefit HSCT patients by shortening the neutropenic phase
to reduce infection, hospitalization time, and cost.
造血干细胞(HSC)移植(HSCT)被认为是一种潜在的治疗选择,
在美国,每年进行血液和骨髓的某些癌症以及超过20,000例HSCT。
然而,HSCT与高风险相关,因为在移植前需要去除患病的骨髓。
移植直到移植的细胞植入并增殖到足以重建患者的免疫力
系统中,患者被认为是贫血,在此期间,他们非常容易受到感染。除了
对患者潜在的危及生命的身体风险,中性粒细胞减少症需要长的住院时间,
在美国,HSCT的成本高达40万美元。临床上的一种现行策略
试验的目的是移植更大的供体造血干细胞库,以缩短造血干细胞减少期。然而,这些方法
都依赖于供体细胞的离体培养,
干细胞的正常功能,并且可能非常昂贵。忒修斯之船的创新解决方案是
一种在移植前短暂、一次性接触供体细胞的药物,
体内扩增我们的药物是核转录因子同源盒蛋白B4的专利突变体
(HOXB 4(m)),其促进HSC扩增而不分化。HOXB 4(m)具有改善的降解
抗性,这使我们能够克服HOXB 4的几个缺点(例如,蛋白质半衰期短,
与遗传过表达相关的骨髓增生性疾病)。通过延长其细胞内半衰期,
HOXB 4(m)对于临床使用是实用的,同时潜在地避免了由组成型HOXB 4(m)引起的不良反应。
过度表达早期临床前数据表明,用HOXB 4(m)处理细胞可以扩增所有主要谱系,
HSC同时保持多能性。然而,HOXB 4(m)的当前递送受到其渗透能力的限制。
细胞和定位在细胞核,其生物活性的网站。
该R61/R33提案的目标是通过改善HOXB 4(m)的核性能来提高其效率和安全性。
交付.这将通过实现三个目标来实现。在目标1(R61)中,我们将执行一个库
筛选以鉴定HOXB 4(m)的细胞穿透肽和核靶向基序的最佳组合
核定位在目标2(R33)中,我们将评估最佳候选药物的体外疗效,以选择电极导线
候选人在目标3(R33)中,我们将证明长期造血重建无不良反应
或我们的主要候选人在小鼠HSCT研究中的体内GVHD。成功完成R61/R33计划
将证明在较低浓度下维持疗效的改良HOXB 4(m)候选物的可行性
暴露时间更短该项目将提供必要的数据,以支持未来广泛的体内
IND申请所需的有效性和安全性研究。有了HOXB 4(m),我们可以绕过原来的
通过缩短血供减少期,改善体内扩增,使HSCT患者受益
以减少感染、住院时间和费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy A Elser其他文献
Jeremy A Elser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy A Elser', 18)}}的其他基金
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant
临床前开发一种核靶向生物制剂,可安全地增加干细胞体内扩增,以加速化疗和骨髓移植后中性粒细胞减少症的恢复
- 批准号:
10448536 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant
干细胞体内扩增的刺激物,可加速化疗和干细胞移植继发的中性粒细胞减少症的恢复
- 批准号:
10324724 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
相似海外基金
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
- 批准号:
NE/Y000080/1 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328975 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
- 批准号:
2400967 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328973 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
- 批准号:
10112700 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328972 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332916 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
- 批准号:
2332917 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
- 批准号:
2328974 - 财政年份:2024
- 资助金额:
$ 23.03万 - 项目类别:
Continuing Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
- 批准号:
23H01186 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)